Skip to main content

Advertisement

SpringerLink
Log in

Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Purpose. To evaluate the concordance between HER2 gene amplification, determined by fluorescence in situ hybridization (FISH), and HER2 protein overexpression assessed by an immunohistochemical (IHC) assay. The IHC protocol used was a research assay, known as the Clinical Trial Assay (CTA), developed to select women with metastatic breast cancer (MBC) for three pivotal clinical trials of trastuzumab therapy.

Methods. A direct-labeled, dual-probe FISH assay was used to determine HER2 amplification in 623 fixed breast cancer tissue specimens. These specimens had been stored as paraffin-embedded sections for 2ᾢ5 years. All specimens had been analyzed for HER2 protein expression by the CTA. To assess the reproducibility of FISH results in archived material, we evaluated a separate group of 617 breast cancer tissue specimens at two di erent laboratories.

Results. Informative FISH results were available for 529 (85%) of the 623 specimens. Overall concordance between FISH and IHC results was 82% (95% CI; 78ᾢ85%). Assay agreement between FISH results and specimens with immunostaining scores of 0, 1+, and 3+ were 97, 93 and 89%, respectively. However, only 24% of specimens with 2+ immunostaining scores had HER2 amplification by FISH; there was assay disagreement in 76% of specimens in this IHC subgroup. Interlaboratory FISH concordance was 92% (95% CI; 89ᾢ94%), indicating very good assay reproducibility in these archived specimens.

Conclusion. HER2 status determined by CTA-IHC and FISH are significantly correlated; however, differences between these two assays can a ect patient selection for trastuzumab therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • T Akiyama C Sudo H Ogawara K Toyoshima T Yamamoto (1986) ArticleTitleThe product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity Science 232 1644–1646 Occurrence Handle3012781

    PubMed  Google Scholar 

  • L Coussens TL Yang-Feng YC Liao E Chen A Gray J McGrath PH Seeburg TA Libermann J Schlessinger U Francke et al. (1985) ArticleTitleTyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene Science 230 1132–1139

    Google Scholar 

  • DF Stern PA Heffernan RA Weinberg (1986) ArticleTitlep185, a product of the neu proto-oncogene, is a receptorlike protein associated with tyrosine kinase activity Mol Cell Biol 6 1729–1740 Occurrence Handle2878363

    PubMed  Google Scholar 

  • DJ Slamon GM Clark SG Wong WJ Levin A Ullrich WL McGuire (1987) ArticleTitleHuman breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177–182

    Google Scholar 

  • G Pauletti S Dandekar H Rong (1998) ArticleTitleA large-scale FISH study of HER-2/neu gene amplification in breast cancer. Proc Am Assoc Cancer Res 39 345

    Google Scholar 

  • DJ Slamon W Godolphin LA Jones JA Holt SG Wong DE Keith WJ Levin SG Stuart J Udove A Ullrich et al. (1989) ArticleTitleStudies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 707–712

    Google Scholar 

  • OP Kallioniemi A Kallioniemi W Kurisu A Thor LC Chen HS Smith FM Waldman D Pinkel JW Gray (1992) ArticleTitleERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization Proc Natl Acad Sci USA 89 5321–5325 Occurrence Handle1351679

    PubMed  Google Scholar 

  • BA Gusterson RD Gelber A Goldhirsch KN Price J Save-Soderborgh R Anbazhagan J Styles CM Rudenstam R Golouh R Reed et al. (1992) ArticleTitlePrognostic importance of c-erbB-2 expression in breast cancer.International (Ludwig) Breast Cancer Study Group J Clin Oncol 10 1049–1056

    Google Scholar 

  • IL Andrulis SB Bull ME Blackstein D Sutherland C Mak S Sidlofsky KP Pritzker RW Hartwick W Hanna L Lickley R Wilkinson A Qizilbash U Ambus M Lipa H Weizel A Katz M Baida S Mariz G Stoik P Dacamara D Strongitharm W Geddie D McCready (1998) ArticleTitleneu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer.Toronto Breast Cancer Study Group J Clin Oncol 16 1340–1349 Occurrence Handle9552035

    PubMed  Google Scholar 

  • MF Press MC Pike VR Chazin G Hung JA Udove M Markowicz J Danyluk W Godolphin M Sliwkowski R Akita et al. (1993) ArticleTitleHer-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease Cancer Res 53 4960–4970 Occurrence Handle8104689

    PubMed  Google Scholar 

  • MF Press L Bernstein PA Thomas LF Meisner JY Zhou Y Ma G Hung RA Robinson C Harris A El-Naggar DJ Slamon RN Phillips JS Ross SR Wolman KJ Flom (1997) ArticleTitleHER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas J Clin Oncol 15 2894–2904 Occurrence Handle9256133

    PubMed  Google Scholar 

  • VR Chazin M Kaleko AD Miller DJ Slamon (1992) ArticleTitleTransformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor Oncogene 7 1859–1866 Occurrence Handle1354348

    PubMed  Google Scholar 

  • P Carter L Presta CM Gorman JB Ridgway D Henner WL Wong AM Rowland C Kotts ME Carver HM Shepard (1992) ArticleTitleHumanization of an anti-p185HER2 antibody for human cancer therapy Proc Natl Acad Sci USA 89 4285–4289 Occurrence Handle1350088

    PubMed  Google Scholar 

  • MA Cobleigh CL Vogel D Tripathy NJ Robert S Scholl L Fehrenbacher JM Wolter V Paton S Shak G Lieberman DJ Slamon (1999) ArticleTitleMultinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease J Clin Oncol 17 2639–2648 Occurrence Handle10561337

    PubMed  Google Scholar 

  • DJ Slamon B Leyland-Jones S Shak H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram J Baselga L Norton (2001) ArticleTitleUse of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783–792 Occurrence Handle10.1056/NEJM200103153441101 Occurrence Handle11248153

    Article  PubMed  Google Scholar 

  • CL Vogel MA Cobleigh D Tripathy JC Gutheil LN Harris L Fehrenbacher DJ Slamon M Murphy WF Novotny M Burchmore S Shak SJ Stewart M Press (2002) ArticleTitleEfficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 719–726 Occurrence Handle10.1200/JCO.20.3.719 Occurrence Handle11821453

    Article  PubMed  Google Scholar 

  • G Pauletti W Godolphin MF Press DJ Slamon (1996) ArticleTitleDetection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization Oncogene 13 63–72 Occurrence Handle8700555

    PubMed  Google Scholar 

  • G Pauletti S Dandekar H Rong L Ramos H Peng R Seshadri DJ Slamon (2000) ArticleTitleAssessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry J Clin Oncol 18 3651–3664 Occurrence Handle11054438

    PubMed  Google Scholar 

  • MF Press G Hung W Godolphin DJ Slamon (1994) ArticleTitleSensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression Cancer Res 54 2771–2777 Occurrence Handle7909495

    PubMed  Google Scholar 

  • RR Tubbs JD Pettay PC Roche MH Stoler RB Jenkins TM Grogan (2001) ArticleTitleDiscrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message J Clin Oncol 19 2714–2721 Occurrence Handle11352964

    PubMed  Google Scholar 

  • A Lebeau D Deimling C Kaltz A Sendelhofert A Iff B Luthardt M Untch U Lohrs (2001) ArticleTitleHer-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization J Clin Oncol 19 354–363 Occurrence Handle11208826

    PubMed  Google Scholar 

  • RE Jimenez T Wallis P Tabasczka DW Visscher (2000) ArticleTitleDetermination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization Mod Pathol 13 37–45 Occurrence Handle10.1038/modpathol.3880007 Occurrence Handle10658908

    Article  PubMed  Google Scholar 

  • JM Bartlett JJ Going EA Mallon AD Watters JR Reeves P Stanton J Richmond B Donald R Ferrier TG Cooke (2001) ArticleTitleEvaluating HER2 amplification and overexpression in breast cancer J Pathol 195 422–428 Occurrence Handle10.1002/path.971 Occurrence Handle11745673

    Article  PubMed  Google Scholar 

  • NM Diaz (2001) ArticleTitleLaboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy Cancer Control 8 415–418 Occurrence Handle11579337

    PubMed  Google Scholar 

  • TW Jacobs AM Gown H Yaziji MJ Barnes SJ Schnitt (1999) ArticleTitleComparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer J Clin Oncol 17 1974–1982 Occurrence Handle10561247

    PubMed  Google Scholar 

  • S Kakar N Puangsuvan JM Stevens R Serenas G Mangan S Sahai ML Mihalov (2000) ArticleTitleHER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival Mol Diagn 5 199–207 Occurrence Handle10.1054/modi.2000.16690 Occurrence Handle11070154

    Article  PubMed  Google Scholar 

  • RL Ridolfi MR Jamehdor JM Arber (2000) ArticleTitleHER-2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach Mod Pathol 13 866–873 Occurrence Handle10.1038/modpathol.3880154 Occurrence Handle10955453

    Article  PubMed  Google Scholar 

  • EA Perez PC Roche RB Jenkins CA Reynolds KC Halling JN Ingle LE Wold (2002) ArticleTitleHER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization Mayo Clin Proc 77 148–154 Occurrence Handle11838648

    PubMed  Google Scholar 

  • TA Thomson MM Hayes JJ Spinelli E Hilland C Sawrenko D Phillips B Dupuis RL Parker (2001) ArticleTitleHER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization Mod Pathol 14 1079–1086 Occurrence Handle10.1038/modpathol.3880440 Occurrence Handle11706067

    Article  PubMed  Google Scholar 

  • MP Hoang AA Sahin NG Ordonez N Sneige (2000) ArticleTitleHER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma Am J Clin Pathol 113 852–859 Occurrence Handle10.1309/VACP-VLQA-G9DX-VUDF Occurrence Handle10874886

    Article  PubMed  Google Scholar 

  • AD Seidman MN Fornier FJ Esteva L Tan S Kaptain A Bach KS Panageas C Arroyo V Valero V Currie T Gilewski M Theodoulou ME Moynahan M Moasser N Sklarin M Dickler G D‘Andrea M Cristofanilli E Rivera GN Hortobagyi L Norton CA Hudis (2001) ArticleTitleWeekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification J Clin Oncol 19 2587–2595 Occurrence Handle11352950

    PubMed  Google Scholar 

  • DL Persons KA Borelli PH Hsu (1997) ArticleTitleQuantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization Mod Pathol 10 720–727 Occurrence Handle9237184

    PubMed  Google Scholar 

  • H Tsuda F Akiyama H Terasaki T Hasegawa M Kurosumi M Shimadzu S Yamamori G Sakamoto (2001) ArticleTitleDetection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer 92 2965–2974

    Google Scholar 

  • P Birner G Oberhuber J Stani C Reithofer H Samonigg H Hausmaninger E Kubista W Kwasny D Kandioler-Eckersberger M Gnant R Jakesz (2001) ArticleTitleEvaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer Clin Cancer Res 7 1669–1675 Occurrence Handle11410505

    PubMed  Google Scholar 

  • MF Press DJ Slamon KJ Flom J Park JY Zhou L Bernstein (2002) ArticleTitleEvaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens J Clin Oncol 20 3095–3105 Occurrence Handle12118023

    PubMed  Google Scholar 

  • S Paik J Bryant E Tan-Chiu E Romond W Hiller K Park A Brown G Yothers S Anderson R Smith DL Wickerham N Wolmark (2002) ArticleTitleReal-world performance of HER2 testingᾢNational Surgical Adjuvant Breast and Bowel Project experience J Natl Cancer Inst 94 852–854 Occurrence Handle12048273

    PubMed  Google Scholar 

  • J Fleiss (1981) Statistical Methods of Rates and Proportions EditionNumber2 John Wiley & Sons, Inc New York 217

    Google Scholar 

  • Mass RD, Press MF, Anderson S: Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer, 2005 (in press).

  • JS Ross JA Fletcher (1998) ArticleTitleThe HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy Stem Cells 16 413–428 Occurrence Handle9831867

    PubMed  Google Scholar 

  • H Battifora M Kopinski (1986) ArticleTitleThe influence of protease digestion and duration of fixation on the immunostaining of keratins A comparison of formalin and ethanol fixation. J Histochem Cytochem 34 1095–1100

    Google Scholar 

  • F Penault-Llorca J Adelaide G Houvenaeghel J Hassoun D Birnbaum J Jacquemier (1994) ArticleTitleOptimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation J Pathol 173 65–75 Occurrence Handle10.1002/path.1711730111 Occurrence Handle7931839

    Article  PubMed  Google Scholar 

  • TW Jacobs AM Gown H Yaziji MJ Barnes SJ Schnitt (1999) ArticleTitleSpecificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system J Clin Oncol 17 1983–1987 Occurrence Handle10561248

    PubMed  Google Scholar 

  • Owens MA Horten BC Da Silva MM (2004) ArticleTitleHER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues Clin Breast Cancer 5 63–69 Occurrence Handle15140287

    PubMed  Google Scholar 

  • Press MF SG, Bernstein L, Mirlacher M, Villalobos I, Zhou J, Riva A, Nabholtz JM, Slamon DJ: Diagnostic evaluation of HER-2/neu as a molecular therapeutic target: local testing versus centralized FISH testing. Lab Invest 83: 43a, 2003

  • GA Niehans TP Singleton D Dykoski DT Kiang (1993) ArticleTitleStability of HER-2/neu expression over time and at multiple metastatic sites J Natl Cancer Inst 85 1230–1235 Occurrence Handle8101229

    PubMed  Google Scholar 

  • A Vincent-Salomon M Jouve P Genin P Freneaux B Sigal-Zafrani M Caly P Beuzeboc P Pouillart X Sastre-Garau (2002) ArticleTitleHER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process Cancer 94 2169–2173 Occurrence Handle10.1002/cncr.10456 Occurrence Handle12001113

    Article  PubMed  Google Scholar 

  • R Simon A Nocito T Hubscher C Bucher J Torhorst P Schraml L Bubendorf MM Mihatsch H Moch K Wilber A Schotzau J Kononen G Sauter (2001) ArticleTitlePatterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer J Natl Cancer Inst 93 1141–1146

    Google Scholar 

  • S Masood MM Bui (2000) ArticleTitleAssessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study Ann Clin Lab Sci 30 259–265 Occurrence Handle10945565

    PubMed  Google Scholar 

  • S Paik E Tan-Chiu J Bryant E Romond A Brown J Mull W Hiller M Finnigan N Wolmark (2002) ArticleTitleSuccessful quality assurance program for HER2 testing in the NSABP trial for Herceptin Breast Cancer Res Treat 76 S31

    Google Scholar 

  • J Bartlett E Mallon T Cooke (2003) ArticleTitleThe clinical evaluation of HER-2 status: which test to use J Pathol 199 411–417 Occurrence Handle10.1002/path.1354 Occurrence Handle12635130

    Article  PubMed  Google Scholar 

  • CAP (2002) ArticleTitleClinical laboratory assays for HER-2/neu amplification and overexpression: quality assurance, standardization, and proficiency testing Arch Pathology Lab Med 126 803–808

    Google Scholar 

  • PJ vDP Diest Particlevan SC Henzen-Logmans E Berns ME Burg Particlevan der J Green I Vergote (1997) ArticleTitleA scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group J Clin Pathol 50 801–804 Occurrence Handle9462258

    PubMed  Google Scholar 

  • JJ Going L Mallon JR Reeves AD Watters J Richmond B Donald R Ferrier T Cooke J Bartlett (2000) ArticleTitleInter-observer agreement in assessing C-ERBB-2 status in breast cancer: immunhistochemistry and FISH. J Pathol 190 IssueID (Suppl) 19A

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Genentech Inc., South San Francisco, CA

    Noël Dybdal, Grazyna Leiberman, Alex Bajamonde, Robert L. Cohen, Robert D. Mass & Corsee Sanders

  2. Laboratory Corporation of America, Research Triangle Park, NC

    Steven Anderson & Bryan McCune

  3. Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA

    Michael F. Press

  4. Genentech Inc., One DNA Way, MS 86, South San Francisco, CA, 94080, USA

    Noël Dybdal

Authors
  1. Noël Dybdal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Grazyna Leiberman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Steven Anderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bryan McCune
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alex Bajamonde
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Robert L. Cohen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Robert D. Mass
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Corsee Sanders
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Michael F. Press
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Noël Dybdal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dybdal, N., Leiberman, G., Anderson, S. et al. Determination of HER2 Gene Amplification by Fluorescence In situ Hybridization and Concordance with the Clinical Trials Immunohistochemical Assay in Women with Metastatic Breast Cancer Evaluated for Treatment with Trastuzumab. Breast Cancer Res Treat 93, 3–11 (2005). https://doi.org/10.1007/s10549-004-6275-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-004-6275-8

Keywords

Search

Navigation